AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
186.68
-0.83 (-0.44%)
At close: Apr 28, 2026, 4:00 PM EDT
186.61
-0.07 (-0.04%)
After-hours: Apr 28, 2026, 7:59 PM EDT
AstraZeneca Employees
AstraZeneca had 95,100 employees as of December 31, 2025. The number of employees increased by 2,200 or 2.37% compared to the previous year.
Employees
95,100
Change (1Y)
2,200
Growth (1Y)
2.37%
Revenue / Employee
$617,655
Profits / Employee
$107,518
Market Cap
291.18B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 95,100 | 2,200 | 2.37% |
| Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
| Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
| Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
| Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
| Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
| Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
| Dec 31, 2013 | 51,500 | -200 | -0.39% |
| Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
| Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
| Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
| Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
| Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
| Dec 31, 2007 | 67,400 | 600 | 0.90% |
| Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
| Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
| Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
| Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
| Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
AZN News
- 16 hours ago - AstraZeneca (AZN) Receives FDA Approval for Breztri Aerosphere in Asthma Treatment - GuruFocus
- 1 day ago - AstraZeneca (AZN) Gains FDA Approval for Saphnelo Self-Administration - GuruFocus
- 1 day ago - SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus - Business Wire
- 1 day ago - AstraZeneca: FDA Approves Saphnelo For Subcutaneous Self-administration - Nasdaq
- 4 days ago - Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics - Nasdaq
- 7 days ago - T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage - GuruFocus
- 7 days ago - AstraZeneca (AZN) Seeks Accelerated Approval for Ultomiris in IgAN Treatment - GuruFocus
- 7 days ago - Germany risks missing out on new drugs, AstraZeneca CEO tells paper - Reuters